Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results DOI Creative Commons
Т. V. Beketova, N. О. Levina,

Yu. A. Uskova

et al.

Rheumatology Science and Practice, Journal Year: 2024, Volume and Issue: 62(5), P. 465 - 473

Published: Oct. 31, 2024

Patients with ANCA-associated systemic vasculitis (AAV) are at risk of severe COVID-19. At the same time, in immunocompromised patients, particular those receiving anti-B cell therapy rituximab (RTX), post-vaccination effect may be insufficient. Since 2022 long-acting virus-neutralizing monoclonal antibodies (MAB) tixagevimab and cilgavimab (Evushheld, AZD7442) have been used as pre-exposure prophylaxis for The aim study is to evaluate effectiveness (TC) COVID-19 its safety RTX treated patients AAV. Materials methods . prospective included 63 AAV RTX. Median age 53 (19– 79) years, M:F 1:1.1. From March June 2023, TC was administered a total dose 300 mg and/or 600 mg. Observation continued until April 2024. In November 2023 2024 telephone online survey conducted simultaneously identify confirmed cases adverse reactions. also Treatment Satisfaction Questionnaire version 9 (TSQM-9). Considering duration (6 months), were divided into two groups depending on interval after last administration TC: up 6 months inclusive – group 1; more than 2. Results During two-year follow-up period, detected 31.7% median between development 5.5 [2–19] months. 1, which 12 COVID-19, 92% had mild form disease, only one lung damage, there no fatal outcomes. 2, cessation accompanied by damage 89% cases, required hospitalization 78%, patients. Four prolonged course persistence SARS-CoV-2 (pCOVID, persistent COVID). 4 including 3 pCOVID, treatment carried out combined antiviral drug nirmarelvir + ritonavir (Skyvira) combination intravenous human immunoglobulin (IVIG) effect. There statistically significant differences incidence secondary immunodeficiency without it (p=0.868). final stage study, serum level IgG examined 34 70.4 (0.33–1086.1) binding antibody units (BAU), indicates lack neutralizing most patients; statistical their (p=0.685). No reactions directly related use observed. A high TSQM-9 global satisfaction domain noted 71.4 (14.3–100); 72,4% respondents answered “satisfied”– “extremely satisfied” first question (effectiveness domain). Conclusions Pre-exposure using RTM safe allowed reduce avoid deaths during period action. After TC, an increase frequency need observed, pCOVID noted. Skyvira IVIG effective all cases. MAB other rheumatic diseases requires further in-depth study.

Language: Английский

High-throughput specificity profiling of antibody libraries using ribosome display and microfluidics DOI Creative Commons

Ellen K. Wagner,

Kyle P. Carter, Yoong Wearn Lim

et al.

Cell Reports Methods, Journal Year: 2024, Volume and Issue: 4(12), P. 100934 - 100934

Published: Dec. 1, 2024

In this work, we developed PolyMap (polyclonal mapping), a high-throughput method for mapping protein-protein interactions. We demonstrated the of thousands antigen-antibody interactions between diverse antibody libraries isolated from convalescent and vaccinated COVID-19 donors set clinically relevant SARS-CoV-2 spike variants. identified over 150 antibodies with variety distinctive binding patterns toward antigen variants found broader profile, including targeting Omicron variant, in repertoires more recent donors. then used these data to select mixtures small number clones complementary reactivity that together provide strong potency broad neutralization. is generalizable platform can be one-pot epitope mapping, immune repertoire profiling, therapeutic design and, future, could expanded other families interacting proteins.

Language: Английский

Citations

1
Improving antibody-mediated protection against HSV infection by eliminating interactions with the viral Fc receptor gE/gI DOI Creative Commons
Matthew D. Slein, Iara M. Backes, Natasha S. Kelkar

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 22, 2024

Herpes simplex virus (HSV) encodes surface glycoproteins that are host defense evasion molecules, allowing the to escape immune clearance. In addition their role in neuropathogenesis and cell-cell spread, E I (gE/gI) form a viral Fc receptor (vFcR) for most subclasses allotypes of human IgG promote humoral responses. While monoclonal antibodies (mAbs) protect mice from neonatal HSV (nHSV) infections, impact vFcR on mAb-mediated protection by binding is unknown. Using HSV-1 with intact ablated gE-mediated binding, Fc-engineered modified ability interact gE/gI, we investigated pathogenesis nHSV. The gD-specific mAb HSV8 lack gE exhibited enhanced neutralization

Language: Английский

Citations

0
Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results DOI Creative Commons
Т. V. Beketova, N. О. Levina,

Yu. A. Uskova

et al.

Rheumatology Science and Practice, Journal Year: 2024, Volume and Issue: 62(5), P. 465 - 473

Published: Oct. 31, 2024

Patients with ANCA-associated systemic vasculitis (AAV) are at risk of severe COVID-19. At the same time, in immunocompromised patients, particular those receiving anti-B cell therapy rituximab (RTX), post-vaccination effect may be insufficient. Since 2022 long-acting virus-neutralizing monoclonal antibodies (MAB) tixagevimab and cilgavimab (Evushheld, AZD7442) have been used as pre-exposure prophylaxis for The aim study is to evaluate effectiveness (TC) COVID-19 its safety RTX treated patients AAV. Materials methods . prospective included 63 AAV RTX. Median age 53 (19– 79) years, M:F 1:1.1. From March June 2023, TC was administered a total dose 300 mg and/or 600 mg. Observation continued until April 2024. In November 2023 2024 telephone online survey conducted simultaneously identify confirmed cases adverse reactions. also Treatment Satisfaction Questionnaire version 9 (TSQM-9). Considering duration (6 months), were divided into two groups depending on interval after last administration TC: up 6 months inclusive – group 1; more than 2. Results During two-year follow-up period, detected 31.7% median between development 5.5 [2–19] months. 1, which 12 COVID-19, 92% had mild form disease, only one lung damage, there no fatal outcomes. 2, cessation accompanied by damage 89% cases, required hospitalization 78%, patients. Four prolonged course persistence SARS-CoV-2 (pCOVID, persistent COVID). 4 including 3 pCOVID, treatment carried out combined antiviral drug nirmarelvir + ritonavir (Skyvira) combination intravenous human immunoglobulin (IVIG) effect. There statistically significant differences incidence secondary immunodeficiency without it (p=0.868). final stage study, serum level IgG examined 34 70.4 (0.33–1086.1) binding antibody units (BAU), indicates lack neutralizing most patients; statistical their (p=0.685). No reactions directly related use observed. A high TSQM-9 global satisfaction domain noted 71.4 (14.3–100); 72,4% respondents answered “satisfied”– “extremely satisfied” first question (effectiveness domain). Conclusions Pre-exposure using RTM safe allowed reduce avoid deaths during period action. After TC, an increase frequency need observed, pCOVID noted. Skyvira IVIG effective all cases. MAB other rheumatic diseases requires further in-depth study.

Language: Английский

Citations

0